For the Pershing Square Capital Management CEO, activist investing is just as much a moral calling as it is a lucrative one
Investors' demands for more profits left patients with the choice to pay up or die.
Toppling Yahoo's entire board or removing one Valeant board member can be hard.
The company's CEO stepped down on Monday
Valeant and a handful other firms may ditch a model that's come under fire.
Valeant is under scrutiny for its business practices.
Valeant Pharmaceuticals is purchasing Sprout for $1 billion.